The US Food and Drug Administration (FDA) has granted fast-track designation to 60 Degrees Pharmaceuticals’ (60P) Tafenoquine for the prevention of malaria in adults.

60P submitted the new drug application (NDA) for Tafenoquine in December last year, seeking approval for the use of the drug in adults who travel to areas prevalent with malaria.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The incidence of malaria infection, which is considered as a life-threatening disease, is reported to have been increasing in travellers returning to the US.

In 2014, the firm signed a cooperative research and development agreement with the US Army Medical Materiel Development Activity (USAMMDA) for the development of the drug as a weekly prophylactic medicine.

“We see fast-track designation as a next step towards marketing this product with a convenient weekly dosing regimen in the US, and eventually around the world.”

60 Degrees Pharmaceuticals CEO Geoffrey Dow said: “We see fast-track designation as a next step towards marketing this product with a convenient weekly dosing regimen in the US, and eventually around the world.

“It is our continued belief our dossier will receive priority review, thereby expediting the review of Tafenoquine. This better positions 60P for a priority review voucher (PRV) thus assisting 60P to acquire needed resources to launch Tafenoquine.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

During an analysis of five clinical trials, carried out to investigate the safety and tolerability of Tafenoquine, the drug was found to be safe and well-tolerated upon administration of the anticipated clinical regimen (ACR).

All five trials are reported to have demonstrated adverse events (AEs), the majority of which were mild or not related to Tafenoquine.